Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma
NL-OMON56050Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Pembrolizumab adjuvant arm with Placebo arm (2 arms). Primary endpoints: Recurrence-free survival, Recurrence-free survival in PD-L1-positive tumors and 1 more. Started Nov 2015; status: recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON56050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56050.